New combo therapy aims to starve liver cancer cells to death
NCT ID NCT05842174
First seen Nov 01, 2025 · Last updated Apr 29, 2026 · Updated 27 times
Summary
This study tests whether adding a drug that blocks a survival process called autophagy can make standard TACE therapy more effective for liver cancer. TACE cuts off blood supply to the tumor, but cancer cells often survive by eating themselves. The new approach aims to stop that and boost the immune system. About 93 adults with unresectable liver cancer will participate.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEPATOCELLULAR CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Corporal Michael J. Crescenz VA Medical Center, Philadelphia, PA
RECRUITINGPhiladelphia, Pennsylvania, 19104-4551, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.